New Wilson’s Disease with Neurological Symptoms: Penicillamine’s Real Risk of Early Neurological Worsening
A new diagnosis, two chelators, and a real difference in early neurological risk between them for her specific presentation.
Maya O., 19, is home from her sophomore year of college after her roommate noticed her speech had started sounding slurred over several weeks, subtle enough at first that Maya herself attributed it to being tired during midterms, along with a slight tremor in her right hand that made her handwriting increasingly hard for her to read back. A slit-lamp exam ordered once her presenting symptoms raised concern found bilateral Kayser-Fleischer rings, and her workup — low serum ceruloplasmin, elevated 24-hour urinary copper, and genetic testing pending but not required to start treatment given how strongly her clinical picture already points one direction — confirmed Wilson's disease, an autosomal recessive disorder of copper metabolism that, left untreated, progresses from exactly the neurological picture she has now toward more severe dysarthria, dystonia, and psychiatric symptoms as copper continues to accumulate in her brain and liver. She has no prior liver symptoms, and her liver enzymes today are only mildly elevated, but her neurological presentation, not a hepatic one, is what brought her in — a distinction that matters directly to the decision in front of her team today.
Copper-chelating therapy is the mainstay of treatment, and penicillamine has the longest history of the two oral chelators available, in continuous use since the 1950s with a well-established record of long-term efficacy. But penicillamine carries a real, specifically neurological risk that trientine largely avoids: a meaningful proportion of Wilson's disease patients, particularly those presenting neurologically rather than hepatically, as Maya is, experience an initial worsening of their neurological symptoms when penicillamine therapy begins, thought to result from the drug's own rapid mobilization of copper from tissue stores into the bloodstream faster than the body can safely clear it — a paradoxical deterioration that can, in a genuine minority of cases, become permanent rather than resolving once chelation continues. Trientine chelates copper through a different binding mechanism and has historically been considered somewhat less potent for rapid initial decoppering, though the strongest recent randomized evidence for the newer formulations, the CHELATE trial (Schilsky et al., 2022), tested trientine tetrahydrochloride against penicillamine only as maintenance therapy in adults already stable on penicillamine for at least a year, and found it non-inferior in that setting. That is not the question Maya presents. Nothing in CHELATE speaks to initiating chelation in a previously untreated patient with neurological disease, and it was not designed to measure initial neurological worsening at all — so the case for choosing trientine here rests on the observed pattern of that worsening risk with penicillamine in neurologically presenting patients, not on a trial that enrolled a different population answering a different question.
New diagnosis, first treatment decision
Maya's presentation is neurological, not hepatic — dysarthria and tremor are what brought her here. Penicillamine has a real, documented risk of paradoxical neurological worsening at initiation specifically in patients presenting this way, thought to come from the drug mobilizing tissue copper into the bloodstream faster than it can be safely cleared. I'd start trientine first-line for her given that risk concentration.
I won't dispute that the neurological-worsening risk is real and specifically relevant to her presentation. Penicillamine still has decades of established efficacy behind it, though, and some clinicians consider its decoppering potency worth that risk when disease could otherwise progress untreated. A slow, low-dose initiation with close monitoring is a reasonable alternative to switching by default.
I'd want to be careful about treating trientine's 'more recent' comparable-efficacy data as fully settled without being specific about which formulations and follow-up periods that data actually covers.
Given her presentation is neurological, I'd go with trientine first-line here. And separate from which chelator wins this debate: pyridoxine supplementation needs to start alongside whichever drug we choose, since penicillamine independently reduces active vitamin B6 — a distinct mechanism from the neurological-worsening question, and not something that should get decided by which chelator we pick.
Agreed: start trientine as first-line chelator specifically because of her neurological presentation, with pyridoxine supplementation started alongside regardless, and low-copper dietary counseling given today. Explicit documentation that penicillamine remains a real fallback option, not a permanently closed door, if trientine doesn't adequately control her disease. Siblings flagged for Wilson's disease screening given the autosomal recessive inheritance pattern, a separate family-level action item agreed without disagreement.